MTI-31

SKU: orb1304105

Description

MTI-31

Research Area

Signal Transduction

Key Properties

• CAS Number: 1567915-38-1
• MW: 474.55
• Purity: 99.97%
• Formula: C₂₆H₃₀N₆O₃
• SMILES: CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1C2CCC1COC2
• Target: mTOR
• Solubility: 10% DMSO+90% Saline:0.5 mg/mL (1.05 mM);DMSO:8.33 mg/mL (17.55 mM)

Bioactivity

• Target IC50:
  mTOR:0.2 nM(Kd)|mTOR:39 nM (ATP=100 μM)
• In Vivo:
  MTI-31(5-40 mg/kg; orally) is efficacious in several tumor models harboring HER2+/PIK3CAmut and/or PTEN-deficiency exemplified by MDA-MB-453 and 786-O. Treatment of tumor bearing nude mice with orally administered MTI-31 inhibits growth of H1975 tumors (25 mg/kg/d; orally) or U87MG tumors (30 mg/kg/d; orally).
• In Vitro:
  MTI-31 (0.01-100 μM) elicits a potent and more substantial inhibition of cell growth than that of Rapamycin. Treatment with MTI-31 for 6 h demonstrates a dose-dependent inhibition of both the mTORC1 substrates P-S6K1(T389), P-S6(S235/6), P-4EBP1(T70) and mTORC2 substrate P-AKT(S473), achieving 50% inhibition at ≤0.12 μM in three representative tumor cell lines harboring mTOR pathway dysregulation (786-O renal, U87MG glioma and MDA-MB-453 breast). MTI-31-induced apoptosis requires mTORC2-regulated Bim- and GSK3 activity.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

apoptosis, Inhibitor, Mammalian target of Rapamycin, EGFR mutant cancer, inhibit, mTORC1, mTORC2, mTOR-TF axis, mTOR, mTOR inhibitor, mTOR kinase inhibitor, MTI 31, MTI31, MTI-31, lipid metabolism, LXI 15029, LXI15029, LXI-15029, tissue factor, tumor microenvironment

Compound Identifiers

PubChem CID

118591386